Compare SHIM & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | SHIM | MSLE |
|---|---|---|
| Founded | 1990 | N/A |
| Country | United States | Canada |
| Employees | N/A | 21 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.2M | 154.6M |
| IPO Year | 2023 | N/A |
| Metric | SHIM | MSLE |
|---|---|---|
| Price | $3.70 | $8.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 133.6K | 77.0K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.95 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $492,844,000.00 | N/A |
| Revenue This Year | $13.99 | N/A |
| Revenue Next Year | $6.94 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.63 | N/A |
| 52 Week Low | $1.58 | $5.44 |
| 52 Week High | $6.76 | $13.39 |
| Indicator | SHIM | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 45.83 | 61.70 |
| Support Level | $3.43 | $6.71 |
| Resistance Level | $4.10 | $9.75 |
| Average True Range (ATR) | 0.34 | 0.74 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 17.20 | 56.54 |
Shimmick Corp is engaged in delivering turnkey infrastructure solutions that strengthen critical markets across water, energy, climate resiliency, and sustainable transportation. It selectively focuses on the following types of infrastructure projects: Water Treatment, Water Resources, and Other Critical Infrastructure. In water treatment projects the company expands, rehabilitates, upgrades, builds and rebuilds water and wastewater treatment infrastructure. In Other Critical Infrastructure projects, It builds, retrofits, expands, rehabilitates, operates, and maintains critical infrastructure, including mass transit, bridges, and military infrastructure. The company has one operating and reportable segment: infrastructure solutions. All of its revenue is derived from the United States.
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.